Use of implantable cardioverter-defibrillators

Future Cardiology

Volumn 6, Issue 6, 2010, Pages 859-870

  Aronow, Wilbert S ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

blockers; angiotensin converting enzyme inhibitors; antiarrhythmic drugs; biventricular pacing; cardioverterdefibrillator; statins; sudden cardiac death; ventricular fibrillation; ventricular tachycardia

Indexed keywords

ALDOSTERONE ANTAGONIST; AMIODARONE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIARRHYTHMIC AGENT; ANTILIPEMIC AGENT; AZIMILIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FISH OIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METOPROLOL; PLACEBO; PROPAFENONE; SOTALOL;

BRUGADA SYNDROME; CARDIAC RESYNCHRONIZATION THERAPY; CARDIOMYOPATHY; CARDIOVASCULAR RISK; CATHETER ABLATION; CIGARETTE SMOKING; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; CORONARY HEMODYNAMICS; DEFIBRILLATOR; DRUG EFFICACY; DRUG TOXICITY; HEART ARREST; HEART ATRIUM FIBRILLATION; HEART ELECTROPHYSIOLOGY; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE ISCHEMIA; HEART PACING; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; INTERMETHOD COMPARISON; MEDICAL SOCIETY; MORTALITY; OVERALL SURVIVAL; PACEMAKER; PNEUMOTHORAX; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; SECONDARY PREVENTION; SUDDEN DEATH; SYNCOPE; THERAPY EFFECT; TRANSIENT ISCHEMIC ATTACK; TREATMENT INDICATION; UNSPECIFIED SIDE EFFECT;

ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CARDIAC PACING, ARTIFICIAL; DEATH, SUDDEN, CARDIAC; DEFIBRILLATORS, IMPLANTABLE; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOLIPIDEMIC AGENTS; MALE; SEX FACTORS; TACHYCARDIA, VENTRICULAR; UNITED STATES; VENTRICULAR FIBRILLATION;

EID: 78650187172     PISSN: 14796678     EISSN: 17448298     Source Type: Journal    
DOI: 10.2217/fca.10.99     Document Type: Review

References (80)

1. Tresch DD, Platia EV, Guarnieri T et al.: Refractory symptomatic ventricular tachycardia and ventricular fbrillation in elderly patients. Am. J. Med. 83, 399-404 (1987).
2. Tresch DD, Troup PJ, Thakur RK et al.: Comparison of effcacy of automatic implantable cardioverter defbrillator in patients older and younger than 65 years of age. Am. J. Med. 90, 717-724 (1991).
3. Moss AJ, Hall WJ, Cannom DS et al.: Improved survival with an implanted defbrillator in patients with coronary disease at high risk for ventricular arrhythmia. N. Engl. J. Med. 335, 1933-1940 (1996)
4. The Antiarrhythmics versus Implantable Defbrillators (AVID) Investigators: A comparison of antiarrhythmic-drug therapy with implantable defbrillators in patients resuscitated from near-fatal ventricular arrhythmias. N. Engl. J. Med. 337, 1576-1583 (1997).
5. Roy D, Green M, Talajic M et al.: Mode of death in the Canadian Implantable Defbrillator Study (CIDS). Circulation 98(Suppl. I), 1-495 (1998).
6. Bokhari F, Newman D, Greene M, Korley V, Mangat I, Dorian P: Long-term comparison of the implantable cardioverter defbrillator versus amiodarone. Eleven-year follow-up of a subset of patients in the Canadian Implantable Defbrillator Study CIDS. Circulation 110, 112-116 (2004).
7. Siebels J, Cappato R, Ruppel R, Schneider MAE, Kuck KH; CASH Investigators: Preliminary results of the Cardiac Arrest Study Hamburg (CASH). Am. J. Cardiol. 72, 109F-113F (1993).
8. Cappato R, Siebels J, Kuck KH: Value of programmed electrical stimulation to predict clinical outcome in the Cardiac Arrest Study Hamburg (CASH). Circulation 98(Suppl. I), I-495-I-496 (1998).
9. Buxton AE, Lee KL, Fisher JD et al.: A randomized study of the prevention of sudden death in patients with coronary artery disease. N. Engl. J. Med. 341, 1882-1890 (1999).
10. Moss AJ, Zareba W, Hall WJ et al.: Prophylactic implantation of a defbrillator in patients with myocardial infarction and reduced ejection fraction. N. Engl. J. Med. 346, 877-883 (2002).
11. Goldenberg I, Moss AJ: Treatment of arrhythmias and use of implantable cardioverter-defbrillators to improve survival in elderly patients with cardiac disease. In: Clinics in Geriatric Medicine on Heart Failure. Aronow WS (Ed.). Elsevier, PA, USA, 205-219 (2007).
12. Kaplan BA, Epstein LM, Albert CM, Stevenson WG: Survival in octogenarians receiving implantable defbrillators. Am. Heart J. 152, 714-719 (2006).
13. Bardy GH, Lee KL, Mark DB et al.: Amiodarone or an implantable cardioverter- defbrillator for congestive heart failure. N. Engl. J. Med. 352, 225-237 (2005)
14. At 45.5-month median follow-up, compared with placebo, ICD therapy signifcantly decreased all-cause mortality by 23%, with an absolute reduction in mortality of 7.2% after 5 years. Singh SN, Fletcher RD, Fisher SG et al.: Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. N. Engl. J. Med. 333, 77-82 (1995).
15. Cairns JA, Connolly SJ, Roberts R et al.: Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT Lancet 349, 675-682 (1997).
16. Greene HL; for the CASCADE Investigators: The CASCADE study. Randomized antiarrhythmic drug therapy in survivors of cardiac arrest in Seattle. Am. J. Cardiol. 72, 70F-74F (1993).
17. Herre J, Sauve M, Malone P, Griffn JC, Helmy I, Langberg JJ: Long-term results of amiodarone therapy in patients with recurrent sustained ventricular tachycardia or ventricular fbrillation. J. Am. Coll. Cardiol. 13, 442-449 (1989).
18. Makikallio TH, Huikuri HV: Association between usage of p-blocking medication and beneft from implantable cardioverter therapy. Am. J. Cardiol. 98, 1245-1247 (2006).
19. Lai HM, Aronow WS, Kruger A et al.: Effect of p blockers, angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, and statins on mortality in patients with implantable cardioverter-defbrillators. Am. J. Cardiol. 102, 77-78 (2008).
20. Kruger A, Aronow WS, Lai H et al.: Prevalence of appropriate cardioverter-defbrillator shocks in 1038 consecutive patients with implantable cardioverter-defbrillators. Am. J. Ther. 16, 323-325 (2009).
21. O'Rourke RA: Role of myocardial revascularization in sudden cardiac death. Circulation 85(Suppl. I), I112-I117 (1992).
22. Bigger JT Jr, for the Coronary Artery Bypass Graft Patch Trial Investigators: Prophylactic use of implanted cardiac defbrillators in patients at high risk for ventricular arrhythmias after coronary artery bypass graft surgery N. Engl. J. Med. 337, 1569-1575 (1997).
23. Seidl K, Hauer B, Schwick NG, Zahn R, Senges J: Comparison of metoprolol and sotalol in preventing ventricular tachyarrhythmias after the implantation of a cardioverter/defbrillator. Am. J. Cardiol. 82, 744-748 (1998).
24. Brodine WN, Tung RT, Lee JK et al.: Effects of p-blockers on implantable cardioverter defbrillator therapy and survival in the patients with ischemic cardiomyopathy from the Multicenter Automatic Defbrillator Implantation Trial-II. Am. J. Cardiol. 96, 691-695 (2005).
25. Bristow MR, Saxon LA, Boehmer J et al.: Cardiac-resynchronization therapy with or without an implantable defbrillator in advanced chronic heart failure. N. Engl. J. Med. 350, 2140-2150 (2004).
26. Lindenfeld J, Feldman AM, Saxon L et al.: Effects of cardiac resynchronization therapy with or without a defbrillator on survival and hospitalizations in patients with New York Heart Association class IV heart failure. Circulation 115, 204-212 (2007).
27. Desai H, Aronow WS, Tsai FS et al.: Statins reduce appropriate cardioverter-defbrillator shocks and mortality in patients with heart failure and combined cardiac resynchronization and implantable cardioverter-defbrillator therapy. J. Cardiovasc. Pharmacol. Therap. 14, 176-179 (2009).
28. Desai H, Aronow WS, Ahn C et al.: Incidence of appropriate cardioverter- defbrillator shocks and mortality in patients with heart failure treated with combined cardiac resynchronization plus implantable cardioverter-defbrillator therapy versus implantable cardioverter-defbrillator therapy. J. Cardiovasc. Pharmacol. Therap. 15, 37-40 (2010).
29. Desai H, Aronow WS, Ahn C et al.: Risk factors for appropriate cardioverter- defbrillator shocks, inappropriate cardioverter-defbrillator shocks, and time to mortality in 549 patients with heart failure. Am. J. Cardiol. 105, 1336-1338 (2010).
30. Poole JE, Johnson GW, Hellkamp AS et al.: Prognostic importance of defbrillator shocks in patients with heart failure. N. Engl. J. Med. 359, 1009-1017 (2008).
31. Blatt JA, Poole JE, Johnson GW et al.: No beneft from defbrillation threshold testing in the SCD-HeFT (Sudden Cardiac Death in Heart Failure trial. J. Am. Coll. Cardiol. 52, 551-556 (2008).
32. Bruch C, Gotzmann M, Sindermann J et al.: Prognostic value of a restrictive mitral flling pattern in patients with systolic heart failure and an implantable cardioverter-defbrillator. Am. J. Cardiol. 97, 676-680 (2006).
33. Daubert JP, Zareba W, Cannom DS et al.: Inappropriate implantable cardioverter- defbrillator shocks in MADIT II. J. Am. Coll. Cardiol. 51, 1357-1365 (2008).
34. Mitchell LB, Pineda EA, Titus JL, Bartosch PM, Benditt DG: Sudden death in patients with implantable cardioverter defbrillators. The importance of post-shock electromechanical dissociation. J. Am. Coll. Cardiol. 39, 1323-1328 (2002).
35. De Sutter J, Tavernier R, De Buyzere M, Jordaens L, De Backer G: Lipid lowering drugs and recurrences of life-threatening ventricular arrhythmias in high-risk patients. J. Am. Coll. Cardiol. 36, 766-772 (2000).
36. Mitchell LB, Powell JL, Gill is AM, Kehl V, Hallstrom AP; AVID Investigators: Are lipid-lowering drugs also antiarrhythmic drugs? An analysis of the antiarrhythmics Versus Implantable Defbrillators (AVID) Trial. J. Am. Coll. Cardiol. 42, 81-87 (2003).
37. Chiu JH, Abdelhadi RH, Chung MK et al.: Effect of statin therapy on risk of ventricular arrhythmia among patients with coronary artery disease and an implantable cardioverter-defbrillator. Am. J. Cardiol. 95, 490-491 (2005).
38. Goldberger JJ, Subacius H, Schaechter A et al.: Effects of statin therapy on arrhythmic events and survival in patients with nonischemic dilated cardiomyopathy. J. Am. Coll. Cardiol. 48, 1228-1233 (2006).
39. Vyas AK, Guo H, Moss AJ et al.: Reduction in ventricular tachyarrhythmias with statins in the Multicenter Automatic Defbrillator Implantatation trial (MADIT)-II. J. Am. Coll. Cardiol. 47, 769-773 (2006).
40. Dickinson MG, Ip JH, Olshansky B et al.: Statin use was associated with reduced mortality in both ischemic and nonischemic cardiomyopathy and in patients with implantable defbrillators: mortality data and mechanistic insights from the Sudden Cardiac Death in Heart Failure trial (SCD-HeFT). Am. Heart J. 153, 573-578 (2007).
41. Leaf A, Albert CM, Josephson M et al.: Prevention of fatal arrhythmias in high-risk subjects by fsh oil n-3 fatty acid intake. Circulation 112, 2762-2768 (2005).
42. Christensen JH, Riahi S, Schmidt EB et al.: Fatty acids and ventricular arrhythmias in patients with ischaemic heart disease and implantable cardioverter defbrillators. Europace 7, 338-344 (2005). (Pubitemid 40790418)
43. Majmudar MD, Tompkins C, Bachmann JM, Blumenthal RS, Marine JE: Effects of lipid-altering therapies on ventricular arrhythmias and sudden cardiac death. Cardiol. Rev. 17, 60-69 (2009).
44. Raitt MH, Connor WE, Morris C et al.: Fish oil supplementation and risk of ventricular tachycardia and ventricular fbrillation in patients with implantable defbrillators: a randomized controlled trial. JAMA 293, 2884-2891 (2005).
45. Brouwer IA, Zock PL, Camm AJ et al.: Effect of fsh oil on ventricular tachyarrhythmia and death in patients with implantable cardioverter defbrillators. The study on omega-3 fatty acids and ventricular arrhythmia (SOFA) randomized trial. JAMA 295, 2673-2679 (2006).
46. Chattipakorn N, Shinlapawittayatorn K, Sungnoon R, Chattipakorn SC: Effects of n-3 polyunsaturated fatty acid on upper limit of vulnerability shocks. Int. J. Cardiol. 107, 299-302 (2006).
47. Ho AT, Pai SM, Timothy P, Pai RG: Effect of concomitant antiarrhythmic therapy on survival in patients with implantable cardioverter defbrillators. PACE 28, 647-653 (2005).
48. Thibodeau JB, Pillarisetti J, Khumri TM, Jones PG, Main ML: Mortality rates and clinical predictors of reduced survival after cardioverter defbrillator implantation. Am. J. Cardiol. 101, 861-864 (2008).
49. Sanchez JM, Greenberg SL, Chen J et al.: Smokers are at markedly increased risk of appropriate defbrillator shocks in a primary prevention population. Heart Rhythm 3, 450-451 (2006).
50. Goldenberg I, Moss AJ, McNitt S et al.: Cigarette smoking and the risk of supra-ventricular and ventricular tachyarrhythmias in high-risk cardiac patients with implantable cardioverter defbrillators. J. Cardiovasc. Electrophysiol. 17, 931-936 (2006).
51. Dorian P, Al-Khalidi HR, Hohnloser SH et al.: Azimilide reduces emergency department visits and hospitalizations in patients with an implantable cardioverter-defbrillator in a placebo-controlled clinical trial. J. Am. Coll. Cardiol. 52, 1076-1083 (2008).
52. Albert CM, Quigg R, Saba S et al.: Sex differences in outcome after implantable cardioverter defbrillator implantation in nonischemic cardiomyopathy. Am. Heart J. 156, 367-372 (2008).
53. Lampert R: Implantable cardioverter-defbrillator use and beneft in women. Cardiol. Rev. 15, 298-303 (2007).
54. Zareba W, Moss AJ, Hall WJ et al.: Clinical course and implantable cardioverter defbrillator therapy in postinfarction women with severe left ventricular dysfunction. J. Cardiovasc. Electrophysiol. 16, 1265-1270 (2005).
55. Peterson PN, Daugherty SL, Wang Y et al.: Gender differences in procedure-related adverse events in patients receiving implantable cardioverter-defbrillator therapy. Circulation 119, 1078-1084 (2009).
56. Elhendy A, Chapman S, Porter TR, Windle J: Association of myocardial ischemia with mortality and implantable cardioverter-defbrillator therapy in patients with coronary artery disease at risk of arrhythmic death. J. Am. Coll. Cardiol. 46, 1721-1726 (2005).
57. Gandhi K, Aronow WS, Desai H et al.: Incidence of appropriate cardioverter-defbrillator shocks and mortality in patients with implantable cardioverter-defbrillators with ischemic cardiomyopathy versus nonischemic cardiomyopathy at 33-month follow-up. Arch. Med. Sci. (2010) (In press).
58. Maron BJ, Shen W-K, Link MS et al.: Effcacy of implantable cardioverter-defbrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy N. Engl. J. Med. 342, 365-373 (2000).
59. Jayatilleke I, Doolan A, Ingles J et al.: Long-term follow-up of implantable cardioverter defbrillator therapy for hypertrophic cardiomyopathy Am. J. cardiol. 93, 1192-1194 (2004).
60. Maron BJ, Spirito P, Shen W-K et al.: Implantable cardioverter- defbrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy JAMA 298, 405-412 (2007). (Pubitemid 47124061)
61. Daubert JP, Zareba W, Rosero SZ et al.: Role of implantable cardioverter defbrillator therapy in patients with long QT syndrome. Am. Heart J. 153, S53-S58 (2007).
62. Brugada P, Brugada R, Brugada J, Geelen P: Use of the prophylactic implantable cardioverter defbrillator for patients with normal hearts. Am. J. Cardiol. 83, 98D-100D (1999).
63. Fontaine G, Prost-Squarcioni C: Implantable cardioverter defbrillator in arrhthmogenic right ventricular cardiomyopathies. Circulation 109, 1445-1447 (2004).
64. LeLorier P, Krahn AD, Klein GJ, Yee R, Skanes AC: Comparison of patients with syncope with left ventricular dysfunction and negative electrophysiologic testing to cardiac arrest survivors and patients with syncope and preserved left ventricular function and impact of an implantable defbrillator. Am. J. Cardiol. 90, 77-79 (2002).
65. Lorga-Filho A, Geelen P, Vanderheyden M et al.: Early beneft of implantable cardioverter defbrillator therapy in patients waiting for cardiac transplantation. Pacing Clin. Electrophysiol. 21, 1747-1751 (1998).
66. Vincent GM, Schwartz PJ, Denjoy I et al.: High effcacy of p blockers in long-QT syndrome type 1. Contribution of noncompliance and QT-prolonging drugs to the occurrence of p blocker treatment "failures." Circulation 119, 215-221 (2009).
67. Aronow WS, Sorbera C, Chagarlamudi A, Tabandeh H, Gupta S, Cohen M: Indications for and long-term survival in patients with automatic implantable cardioverter-defbrillators. Cardiol. Rev. 13, 50-51 (2005).
68. Bristow MR, Saxon LA, Boehmer J et al.: Cardiac-resynchronization therapy with or without an implantable defbrillator in advanced chronic heart failure. N. Eng. J. Med. 350, 2140-2150 (2004).
69. Hohnloser SH, Kuck KH, Dorian P et al.: Prophylactic use of an implantable cardioverter-defbrillator after acute myocardial infarction. N. Engl. J. Med. 351, 2481-2488 (2004).
70. Jessup M, Abraham WT, Casey DE et al.: 2009 focused update: ACCF/AHA guidelines for the diagnosis and management of heart failure in adults. A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the International Society for Heart and Lung Transplantation. J. Am. Coll. Cardiol. 53, 1343-1382 (2009).
71. Epstein AE, DiMarco JP, Ellenbogen KA et al.: ACC/AHA/HRS guidelines for device-based therapy of cardiac rhythm abnormalities: executive summary. A report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices). Developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. J. Am. Coll. Cardiol. 51, 2085-2105 (2008).
72. Tsai F, Aronow WS, Devabhaktuni S et al.: Prevalence of complications during implantation and during 38-month follow-up of 1060 consecutive patients with implantable cardioverter-defbrillators. Am. J. Ther. 17, E8-E10 (2010).
73. Swerdlow CD, Gunderson BD, Ousdigian KT et al.: Downloadable algorithm to reduce inappropriate shocks caused by fractures of implantable cardioverter-defbrillator leads. Circulation 118, 2122-2129 (2008).
74. Eckstein J, Koller MT, Zabel M et al.: Necessity for surgical revision of defbrillator leads implanted long-term. Causes and management. Circulation 117, 2727-2733 (2008).
75. The DAVID Trial Investigators: Dual-chamber pacing or ventricular backup pacing in patients with an implantable defbrillator. The Dual Chamber and VVI Implantable Defbrillator (DAVID) Trial. JAMA 288, 3115-3123 (2002).
76. Sukhija R, Aronow WS, Sorbera C, Yalamanchili K, Cohen M: Patients, mean age 70 years, with dual-chamber rate- responsive pacing (DDDR-70) have a higher mortality than patients with backup ventricular pacing (VVI-40) at 3.7-year follow-up. J. Gerontol. Med. Sci. 60A, M603-M604 (2005).
77. Sukhija R, Aronow WS, Sorbera C et al.: Left ventricular ejection fraction and prevalence of new left ventricular wall motion abnormality at long-term follow-up in patients treated with dual-chamber rate-responsive pacing at a rate of 70/minute versus backup ventricular pacing at a rate of 40/minute. Am. J. Cardiol. 96, 412-413 (2005).
78. Sukhija R, Aronow WS, Sorbera C, Peterson SJ, Frishman WH, Cohen M: Mortality, left ventricular ejection fraction, and revalence of new left ventricular wall motion abnormality in patients with implantable cardioverter-defbrillators treated with biventricular pacing versus right venricular pacing. Am. J. Ther. 14, 328-330 (2007).
79. Stevenson WG, Chaitman BR, Ellenbogen KA et al.: Clinical assessment and management of patients with implanted cardioverter-defbrillators presenting to nonelectrophysiologists. Circulation 110, 3866-3869 (2004).
80. Reddy VY, Reynolds MR, Neuzil P et al.: Prophylactic catheter ablation for the prevention of defbrillator therapy. N. Engl. J. Med. 357, 2657-2665 (2007).